# EDGAR Filing Document

**Accession Number:** 0001626644
**File Stem:** 0001683168-25-007462
**Filing Date:** 2025-10
**Character Count:** 33565
**Document Hash:** b5f80079c55c4e1f7a50587867d220db
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001683168-25-007462.hdr.sgml**: 20251008

**ACCESSION NUMBER**: 0001683168-25-007462

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251003

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251008

**DATE AS OF CHANGE**: 20251008

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Odyssey Health, Inc.
- **CENTRAL INDEX KEY:** 0001626644
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 471022125
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0731

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-56196
- **FILM NUMBER:** 251383081

**BUSINESS ADDRESS:**
- **STREET 1:** 2300 WEST SAHARA AVENUE
- **STREET 2:** SUITE 800-#4012
- **CITY:** LAS VEGAS
- **STATE:** NV
- **ZIP:** 89102
- **BUSINESS PHONE:** 702-780-6559

**MAIL ADDRESS:**
- **STREET 1:** 2300 WEST SAHARA AVENUE
- **STREET 2:** SUITE 800-#4012
- **CITY:** LAS VEGAS
- **STATE:** NV
- **ZIP:** 89102

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Odyssey Group International, Inc.
- **DATE OF NAME CHANGE:** 20141128

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report: **October 3, 2025**

(Date of earliest event reported)

**<u>ODYSSEY HEALTH, INC.</u>**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **<u>Nevada</u>** | **<u>000-56196</u>** | **<u>47-1022125</u>** |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification Number) |

---

---

| | |
|:---|:---|
| **<u>2300 West Sahara Avenue, Suite 800 - #4012,<br> Las Vegas, NV</u>** | **<u>89102</u>** |
| (Address of principal executive offices) | (Zip Code) |

---

**<u>(702) 780-6559</u>**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(g) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each Class** | **Trading Symbol** | **Name of Each Exchange on Which Registered** |
| Common Stock ($0.001 par value) | ODYY | OTCQB |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b2 of the Securities Exchange Act of 1934 (§240.12b2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

| | |
|:---|:---|
| **Item 1.01.** | **Entry into a Material Definitive Agreement.** |

---

On October 3, 2025, Odyssey Health, Inc., (the "Company" or "Odyssey"), received one hundred thousand dollars ($100,000) related to a Promissory Note Agreement (the "Note") with Peter D'Arruda, an accredited private investor, that was entered into by all parties on October 3, 2025 and effective as of October 1, 2025. The Note is a one-year note, bearing an interest rate of eighteen percent (18%) per annum. In addition, the Company issued to the investor a warrant to purchase one hundred thousand (100,000) shares of Odyssey common stock at Ten cents ($0.10) per share.

---

| | |
|:---|:---|
| **Item 2.03.** | **Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.** |

---

The information set forth above under Item 1.01 is hereby incorporated by reference into this Item 2.03.

---

| | |
|:---|:---|
| **Item 9.01.** | **Financial Statements and Exhibits.** |

---

**(d) Exhibits.**

---

| | |
|:---|:---|
| Number | Exhibit |
| 10.1 | [Promissory Note](odyssey_ex1001.htm) |
| 10.2 | [Warrant](odyssey_ex1002.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Odyssey Health, Inc.** | **Odyssey Health, Inc.** |
| Date: October 8, 2025 | By: | /s/ Joseph Michael Redmond |
|  |  | Joseph Michael Redmond<br> Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

**PROMISSORY NOTE**

**THIS PROMISSORY NOTE** (the "Note") is made as of the 1st day of October 2025, by and between Odyssey Health, Inc., Nevada corporation, (hereinafter known as "BORROWER") and Peter J. D'Arruda, an individual (hereinafter known as "LENDER"), whose address is 124 Poppleford Place, Cary, NC 27518. BORROWER and LENDER shall collectively be known herein as "the Parties". In determining the rights and duties of the Parties under this Note, the entire document must be read as a whole.

**PROMISSORY NOTE**

**FOR VALUE RECEIVED,** BORROWER promises to pay to the order of LENDER the sum of **$100,000 (One hundred thousand dollars)** (hereinafter the "Loan Amount") representing a cash loan from LENDER to BORROWER. The entire outstanding Loan Amount shall bear interest at a rate of eighteen (18%) percent per annum, and shall be paid in full on the dates below.

**ADDITIONAL LOAN TERMS**

The Parties hereby further set forth their rights and obligations to one another under this Loan Agreement and agree to be legally bound as follows:

&nbsp;&nbsp;&nbsp;&nbsp;A. **Maturity. The Note, an** d any accrued interest, will be due in full on September 30, 2026, (the "Maturity
Date"). However, BORROWER may pay off the loan and interest at any time prior to the maturity Date at the BORROWER's discretion.
Notwithstanding the foregoing, the unpaid principal of this Note, and any interest, shall become immediately due and payable upon the
insolvency of the BORROWER, the commission of any act of bankruptcy by the BORROWER, the execution by the BORROWER of a general assignment
for the benefit of creditors, the filing by or against the BORROWER of a petition in bankruptcy, or the appointment of a receiver or trustee
to control the Company in any way.

&nbsp;&nbsp;&nbsp;&nbsp;B. **Parties that are not individuals**. If any party to this agreement is other than an individual (i.e.,
a Corporation, a Limited Liability Company, a Partnership, or a Trust), said Party, and the individual signing on behalf of said Party,
hereby represents and warrants that all steps and actions have been taken under the entity's governing instruments to authorize
the entry into this Loan Agreement. Breach of any representation contained in this paragraph is considered a material breach of the Loan
Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;C. **Integration.** This Loan Agreement sets forth the entire agreement between the Parties with regard
to the subject matter hereof. All prior agreements, representations and warranties, expressed or implied, oral or written with respect
to the subject matter hereof, are hereby superseded by this Loan Agreement. This is an integrated Loan Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;D. **Severability.** In the event any provision of this Loan Agreement is deemed to be void, invalid,
or unenforceable, that provision shall be severed from the remainder of this Loan Agreement so as not to cause the invalidity or unenforceability
of the remainder of this Loan Agreement. All remaining provisions of this Agreement shall then continue in full force and effect. If any
provision shall be deemed invalid due to its scope or breadth, such provision shall be deemed valid to the extent of the scope and breadth
permitted by law.

&nbsp;&nbsp;&nbsp;&nbsp;E. **Modification.** Except as otherwise provided in this document, this Loan Agreement may be modified,
superseded, or voided only upon the written and signed agreement of the Parties. Further, the physical destruction or loss of this document
shall not be construed as a modification or termination of the Loan Agreement contained herein.

&nbsp;&nbsp;&nbsp;&nbsp;F. **Exclusive Jurisdiction for Suit in Case of Breach.** The parties, by entering into this Loan Agreement,
submit to jurisdiction in the State of Nevada for adjudication of any disputes and/or claims between the parties under this Loan Agreement.
Furthermore, the Parties hereby agree that the courts of the State of Nevada shall have exclusive jurisdiction over any disputes between
the Parties relative to this Loan Agreement, whether said disputes sounds in contract, tort, or other areas of the law.

&nbsp;&nbsp;&nbsp;&nbsp;G. **State Law.** This Loan Agreement shall be interpreted under, and governed by, the laws of the State
of Nevada.

**IN WITNESS WHEREOF,** and acknowledging acceptance and agreement of the foregoing, BORROWER, and LENDER affix their signatures hereto,

---

| | | | |
|:---|:---|:---|:---|
| **Odyssey Health , Inc.** | **Odyssey Health , Inc.** | **Peter D'Arruda** | **Peter D'Arruda** |
| */s/ J. Michael Redmond* | */s/ J. Michael Redmond* | */s/ Peter D'Arruda* | */s/ Peter D'Arruda* |
| By: | J. Michael Redmond | By: | Peter D'Arruda |
| Title: | President and CEO |  | An Individual |
| Dated: | October 1, 2025 | Dated: | October 1, 2025 |

---

## Exhibit 10.2

**Exhibit 10.2**

THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS WARRANT UNDER SAID ACT AND ANY APPLICABLE STATE SECURITIES LAWS OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

Right to purchase 100,000 shares of Common Stock of

Odyssey Health, Inc. (subject to adjustment as provided herein)

**COMMON STOCK PURCHASE WARRANT**

100,000 Issue Date: October 1, 2025 WAR-077

Odyssey Health, Inc. a corporation organized under the laws of the State of Nevada hereby certifies that, for value received, the undersigned, or their assigns (the "<u>Holder</u>"), is entitled, subject to the terms set forth below, to purchase from the Company (as defined herein) at any time commencing at any time after the Issue Date of this Warrant until the five (5) year anniversary of the above-referenced date, but subject to Section 1.4 below, up to 100,000 fully paid and non-assessable shares of Common Stock (as hereinafter defined), $0.001 par value per share, at the applicable Exercise Price per share (as defined below). The number and character of such shares of Common Stock and the applicable Exercise Price per share are subject to adjustment as provided herein.

As used herein the following terms, unless the context otherwise requires, have the following respective meanings:

The term "Common Stock" includes (i) the Company's common stock, par value $0.001 per share; and (ii) any other securities into which or for which any of the securities described in the preceding clause (i) may be converted or exchanged pursuant to a plan of recapitalization, reorganization, merger, sale of assets or otherwise.

The term "Company" shall include Odyssey Health, Inc., a Nevada corporation, and any person or entity, which shall succeed, or assume the obligations of, Odyssey Health, Inc. hereunder.

The "Exercise Price" applicable under this Warrant shall be ten cents ($0.10) per share.

The term "Other Securities" refers to any stock (other than Common Stock) and other securities of the Company or any other person (corporate or otherwise) which the holder of the Warrant at any time shall be entitled to receive, or shall have received, on the exercise of the Warrant, in lieu of or in addition to Common Stock, or which at any time shall be issuable or shall have been issued in exchange for or in replacement of Common Stock or Other Securities pursuant to Section 4 or otherwise.

<u>Exercise of Warrant</u>.

<u>Number of Shares Issuable upon Exercise</u>. From and after the date hereof, the Holder shall be entitled to receive, upon exercise of this Warrant in whole or in part, by delivery of an original or fax copy of an exercise notice in the form attached hereto as Exhibit A (the "<u>Exercise Notice</u>"), shares of Common Stock of the Company, subject to adjustment pursuant to Section 4.

<u>Company Acknowledgment</u>. In the event the Holder elects to purchase only a portion of the Common Stock available under the Warrants, the Company will, at the time of the exercise of this Warrant and upon the request of the Holder hereof, acknowledge in writing the number of shares of Common Stock to which such Holder shall continue to be entitled to purchase after such exercise and in accordance with the provisions of this Warrant. If the Holder shall fail to make any such request, such failure shall not affect the continuing obligation of the Company to afford to such holder any such rights.

<u>Trustee for Warrant Holders</u>. In the event that a bank or trust company shall have been appointed as trustee for the Holders of this Warrant pursuant to Subsection 3.2, such bank or trust company shall have all the powers and duties of a warrant agent (as hereinafter described) and shall accept, in its own name for the account of the Company or such successor person as may be entitled thereto, all amounts otherwise payable to the Company or such successor, as the case may be, on exercise of this Warrant pursuant to this Section 1.

<u>Termination of Warrant</u>. In the event the Warrants are not exercised within five (5) Year and One (1) day from the Issue Date, the right to exercise shall terminate.

<u>Procedure for Exercise</u>.

<u>Delivery of Stock Certificates, Etc., on Exercise</u>. The Company agrees that the shares of Common Stock purchased upon exercise of this Warrant shall be deemed to be issued to the Holder as the record owner of such shares as of the close of business on the date on which this Warrant shall have been surrendered and payment made for such shares in accordance herewith. As soon as practicable after the exercise of this Warrant in full or in part, and in any event within Three (3) business days thereafter ("Warrant Share Delivery Date"), the Company shall, at its expense (including the payment by it of any applicable issue taxes), cause to be issued in the name of and delivered to the Holder, or as such Holder (upon payment by such Holder of any applicable transfer taxes) may direct in compliance with applicable securities laws, a certificate or certificates for the number of duly and validly issued, fully paid and non-assessable shares of Common Stock to which such Holder shall be entitled on such exercise. The Company understands that a delay in the delivery of the Warrant Shares after the Warrant Share Delivery Date could result in economic loss to the Holder. Furthermore, in addition to any other remedies which may be available to the Holder, in the event that the Company fails for any reason to effect delivery of the Warrant Shares by the Warrant Share Delivery Date, the Holder may revoke all or part of the relevant Warrant exercise by delivery of a notice to such effect to the Company, whereupon the Company and the Holder shall each be restored to their respective positions immediately prior to the exercise of the relevant portion of this Warrant.

<u>Exercise</u>. Payment must be made by the Holder by wire transfer of immediately available funds or by certified or official bank check payable to the order of the Company equal to the applicable aggregate Exercise Price, and the Holder shall thereupon be entitled to receive the number of duly authorized, validly issued, fully paid and non-assessable shares of Common Stock (or Other Securities) determined as provided herein.

<u>Effect of Reorganization, Etc.; Adjustment of Exercise Price</u>.

<u>Reorganization, Consolidation, Merger, Etc</u>. If there occurs any capital reorganization or any reclassification of the Common Stock of the Company, the consolidation or merger of the Company with or into another person (other than a merger or consolidation of the Company in which the Company is the continuing entity and which does not result in any reorganization or reclassification of its outstanding Common Stock) or the sale or conveyance of all or substantially all of the assets of the Company to another person, then, as a condition precedent to any such reorganization, reclassification, consolidation, merger, sale or conveyance, the Holder will be entitled to receive upon surrender of the Warrant to the Company (a) to the extent there are cash proceeds resulting from the consummation of such reorganization, reclassification, consolidation, merger, sale or conveyance, in exchange for such Warrant, cash in an amount equal to the cash proceeds that would have been payable to the Holder had the Holder exercised such Warrant immediately prior to the consummation of such reorganization, reclassification, consolidation, merger, sale or conveyance, less the aggregate Exercise Price payable upon exercise of the Warrant, and (b) to the extent that the Holder would be entitled to receive Common Stock (or Other Securities) (in addition to or in lieu of cash in connection with any such reorganization, reclassification, consolidation, merger, sale or conveyance), the same kind and amounts of securities or other assets, or both, that are issuable or distributable to the holders of outstanding Common Stock (or Other Securities) of the Company with respect to their Common Stock (or Other Securities) upon such reorganization, reclassification, consolidation, merger, sale or conveyance, as would have been deliverable to the Holder had the Holder exercised such Warrant immediately prior to the consummation of such reorganization, reclassification, consolidation, merger, sale or conveyance less an amount of such securities having a value equal to the aggregate Exercise Price payable upon exercise of the Warrant.

<u>Dissolution</u>. In the event of any dissolution of the Company following the transfer of all or substantially all of its properties or assets, the Company, concurrently with any distributions made to holders of its Common Stock, shall at its expense deliver or cause to be delivered to the Holder the stock and other securities and property (including cash, where applicable) receivable by the Holder pursuant to Section 3.1, or, if the Holder shall so instruct the Company, to a bank or trust company specified by the Holder and having its principal office in New York, NY as trustee for the Holder (the "Trustee").

<u>Continuation of Terms</u>. Upon any reorganization, consolidation, merger or transfer (and any dissolution following any transfer) referred to in this Section 3, this Warrant shall continue in full force and effect and the terms hereof shall be applicable to the shares of stock and other securities and property receivable on the exercise of this Warrant after the consummation of such reorganization, consolidation or merger or the effective date of dissolution following any such transfer, as the case may be, and shall be binding upon the issuer of any such stock or other securities, including, in the case of any such transfer, the person acquiring all or substantially all of the properties or assets of the Company, whether or not such person shall have expressly assumed the terms of this Warrant as provided in Section 4. In the event this Warrant does not continue in full force and effect after the consummation of the transactions described in this Section 3, then the Company's securities and property (including cash, where applicable) receivable by the Holder will be delivered to the Holder or the Trustee as contemplated by Section 3.2.

<u>Extraordinary Events Regarding Common Stock</u>. In the event that the Company shall (a) issue additional shares of the Common Stock as a dividend or other distribution on outstanding Common Stock or any preferred stock issued by the Company (b) subdivide its outstanding shares of Common Stock, or (c) combine its outstanding shares of the Common Stock into a smaller number of shares of the Common Stock, then, in each such event, the Exercise Price shall, simultaneously with the happening of such event, be adjusted by multiplying the then Exercise Price by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding immediately prior to such event and the denominator of which shall be the number of shares of Common Stock outstanding immediately after such event, and the product so obtained shall thereafter be the Exercise Price then in effect. The Exercise Price, as so adjusted, shall be readjusted in the same manner upon the happening of any successive event or events described herein in this Section 4. The number of shares of Common Stock that the Holder shall thereafter, on the exercise hereof as provided in Section 1, be entitled to receive shall be adjusted to a number determined by multiplying the number of shares of Common Stock that would otherwise (but for the provisions of this Section 4) be issuable on such exercise by a fraction of which (a) the numerator is the Exercise Price that would otherwise (but for the provisions of this Section 4) be in effect, and (b) the denominator is the Exercise Price in effect on the date of such exercise (taking into account the provisions of this Section 4). Notwithstanding the foregoing, in no event shall the Exercise Price be less than the par value of the Common Stock.

<u>Certificate as to Adjustments</u>. In each case of any adjustment or readjustment in the shares of Common Stock (or Other Securities) issuable on the exercise of this Warrant, the Company at its expense will promptly cause its Chief Financial Officer or other appropriate designee to compute such adjustment or readjustment in accordance with the terms of this Warrant and prepare a certificate setting forth such adjustment or readjustment and showing in detail the facts upon which such adjustment or readjustment is based, including a statement of (a) the consideration received or receivable by the Company for any additional shares of Common Stock (or Other Securities) issued or sold or deemed to have been issued or sold, (b) the number of shares of Common Stock (or Other Securities) outstanding or deemed to be outstanding, and (c) the Exercise Price and the number of shares of Common Stock to be received upon exercise of this Warrant, in effect immediately prior to such adjustment or readjustment and as adjusted or readjusted as provided in this Warrant. The Company will forthwith mail a copy of each such certificate to the Holder and any warrant agent of the Company (appointed pursuant to Section 10 hereof).

<u>Reservation of Stock, Etc., Issuable on Exercise of Warrant</u>. The Company will at all times reserve and keep available, solely for issuance and delivery on the exercise of this Warrant, shares of Common Stock (or Other Securities) from time to time issuable on the exercise of this Warrant.

<u>Assignment; Exchange of Warrant</u>. Subject to compliance with applicable securities laws, this Warrant, and the rights evidenced hereby, may be transferred by any registered holder hereof (a "Transferor") in whole or in part. On the surrender for exchange of this Warrant, with the Transferor's endorsement in the form of Exhibit B attached hereto (the "Transferor Endorsement Form") and together with evidence reasonably satisfactory to the Company demonstrating compliance with applicable securities laws, which shall include, without limitation, the provision of a legal opinion from the Transferor's counsel (at the Company's expense) that such transfer is exempt from the registration requirements of applicable securities laws, the Company at its expense (but with payment by the Transferor of any applicable transfer taxes) will issue and deliver to or on the order of the Transferor thereof a new Warrant of like tenor, in the name of the Transferor and/or the transferee(s) specified in such Transferor Endorsement Form (each a "Transferee"), calling in the aggregate on the face or faces thereof for the number of shares of Common Stock called for on the face or faces of the Warrant so surrendered by the Transferor.

<u>Replacement of Warrant</u>. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of any such loss, theft or destruction of this Warrant, on delivery of an indemnity agreement or security reasonably satisfactory in form and amount to the Company or, in the case of any such mutilation, on surrender and cancellation of this Warrant, the Company at its expense will execute and deliver, in lieu thereof, a new Warrant of like tenor.

<u>Maximum Exercise</u>. Notwithstanding anything herein to the contrary, in no event shall the Holder be entitled to exercise any portion of this Warrant in excess of that portion of this Warrant upon exercise of which the sum of (a) the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and (b) the number of shares of Common Stock issuable upon the exercise of the portion of this Warrant with respect to which the determination of this limitation is being made, would result in beneficial ownership by the Holder and its Affiliates of any amount greater than 4.99% of the then outstanding shares of Common Stock. As used herein, the term "Affiliate" means any person or entity that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a person or entity, as such terms are used in and construed under Rule 144 under the Securities Act. For purposes of the second preceding sentence, beneficial ownership shall be determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and Regulations 13(d)-(g) thereunder.

<u>Warrant Agent</u>. The Company may, by written notice to the Holder of the Warrant, appoint an agent for the purpose of issuing Common Stock (or Other Securities) on the exercise of this Warrant pursuant to Section 1, exchanging this Warrant pursuant to Section 7, and replacing this Warrant pursuant to Section 8, or any of the foregoing, and thereafter any such issuance, exchange or replacement, as the case may be, shall be made at such office by such agent.

<u>Transfer on the Company's Books</u>. Until this Warrant is transferred on the books of the Company, the Company may treat the registered holder hereof as the absolute owner hereof for all purposes, notwithstanding any notice to the contrary.

<u>Notices, Etc</u>. All notices and other communications from the Company to the Holder shall be either emailed to the email address provided by the Holder, or mailed by first class registered or certified mail, postage prepaid, at such address as may have been furnished to the Company in writing by such Holder or, until any such Holder furnishes to the Company an address, then to, and at the address of, the last Holder who has so furnished an address to the Company.

<u>Miscellaneous</u>. This Warrant and any term hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought. THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEVADA WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAWS. ANY ACTION BROUGHT CONCERNING THE TRANSACTIONS CONTEMPLATED BY THIS WARRANT SHALL BE BROUGHT ONLY IN THE STATE COURTS OF NEVADA OR IN THE FEDERAL COURTS LOCATED IN THE STATE OF NEVADA; PROVIDED, HOWEVER, THAT THE HOLDER MAY CHOOSE TO WAIVE THIS PROVISION AND BRING AN ACTION OUTSIDE THE STATE OF NEVADA. The individuals executing this Warrant on behalf of the Company agree to submit to the jurisdiction of such courts and waive trial by jury. The prevailing party shall be entitled to recover from the other party its reasonable attorneys' fees and costs. In the event that any provision of this Warrant is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of this Warrant. The headings in this Warrant are for purposes of reference only, and shall not limit or otherwise affect any of the terms hereof. The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision hereof. The Company acknowledges that legal counsel participated in the preparation of this Warrant and, therefore, stipulates that the rule of construction that ambiguities are to be resolved against the drafting party shall not be applied in the interpretation of this Warrant to favor any party against the other party.

[SIGNATURE PAGE TO FOLLOW]

IN WITNESS WHEREOF, the Company has executed this Warrant as of the date first written above.

Odyssey Health, Inc.,

<u>/s/ J. Michael Redmond</u> 

Name: J. Michael Redmond

Title: President and CEO

**EXHIBIT A**

**FORM OF SUBSCRIPTION**<br> (To Be Signed Only On Exercise Of Warrant)

---

| | |
|:---|:---|
| TO: | Odyssey Health, Inc. |
|  | 2300 West Sahara Avenue, Suite 800-4012 |
|  | Las Vegas, NV 89102 |
|  | Attention: Chief Executive Officer |

---

The undersigned, pursuant to the provisions set forth in the attached Warrant (No. WAR-076), hereby irrevocably elects to purchase (check applicable box):

---

| | |
|:---|:---|
| <u> </u> | _______________ shares of the Common Stock covered by such Warrant; or |
|  | (insert number) |
| | the maximum number of shares of Common Stock covered by such Warrant |

---

The undersigned herewith makes payment of the full Exercise Price for such shares at the price per share provided for in such Warrant, which is fifty cents ($0.50). Such payment takes the form of (check applicable box or boxes):

---

| | |
|:---|:---|
| <u> </u> | $_____________ by wire transfer of immediately available funds; and/or |
| | $_____________ by cashier's check |

---

The undersigned requests that the certificates for such shares be issued in the name of, and delivered to __________________________________ whose address is ________________________________________.

The undersigned represents and warrants that all offers and sales by the undersigned of the securities issuable upon exercise of the within Warrant shall be made pursuant to registration of the Common Stock under the Securities Act of 1933, as amended (the "Securities Act") or pursuant to an exemption from registration under the Securities Act.

---

| | | |
|:---|:---|:---|
| Dated: | <u> </u> | <u> </u> |
|  |  | (Signature must conform to name of Holder as specified on the face of the Warrant) |
|  |  | Address:<br>|

---

**EXHIBIT B**

**FORM OF TRANSFER OR ENDORSEMENT**<br> (To Be Signed Only On Transfer Of Warrant)

For value received, the undersigned hereby sells, assigns, and transfers unto the person(s) named below under the heading "Transferees" the right represented by the within Warrant to purchase the percentage and number of shares of Common Stock of Odyssey Health, Inc. into which the within Warrant relates specified under the headings "Percentage Transferred" and "Number Transferred," respectively, opposite the name(s) of such person(s) and appoints each such person Attorney to transfer its respective right on the books of Odyssey Health, Inc. with full power of substitution in the premises.

---

| | | | |
|:---|:---|:---|:---|
| <u>Transferees</u> | <u>Address</u> | <u>Percentage</u><br> <u>Transferred</u> | <u>Number <br> Transferred</u> |

---

---

| | | |
|:---|:---|:---|
| Dated: | <u> </u> | <u> </u> |
|  |  | (Signature must conform to name of Holder as specified on the face of the Warrant) |
|  |  | Address:<br>|
|  |  | SIGNED IN THE PRESENCE OF: |
|  |  | (Name) |

---

---

| |
|:---|
| ACCEPTED AND AGREED: |
| [TRANSFEREE] |
| (Name) |

---

<br>